Briana E. Mork
Briana E. Mork has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Andrea R Masters
Clinical Pharmacology Analytical Core-Indiana University Simon Cancer Center, Indiana University School of Medicine, Indianapolis, United States
1 shared publicationAnthony J Baucum
Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, United States
1 shared publication- Bradley K. Taylor
Department of Anesthesiology and Perioperative Medicine, Department of Pharmacology, Pittsburgh Center for Pain Research, and Pittsburgh Project to End Opioid Misuse, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
1 shared publication - Brady K. Atwood
Department of Pharmacology, University of Minnesota Medical School, Minneapolis, MN 55455, USA
1 shared publication Bryan K Yamamoto
Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, United States
1 shared publicationCameron W Morris
Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, United States
1 shared publication
Latest Publications
- Open Access
- 16 November 2021
- Published by Elsevier in Neuropharmacology
- Vol. 203, 108885
Sphingosine-1-phosphate receptor 1 agonist SEW2871 alters membrane properties of late-firing somatostatin expressing neurons in the central lateral amygdala
- 16 November 2021
- Published by Elsevier in Neuropharmacology
- Vol. 203, 108885
Open AccessSphingosine-1-phosphate receptor 1 agonist SEW2871 alters membrane properties of late-firing somatostatin expressing neurons in the central lateral amygdala
- Open Access
- 16 March 2021
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 10
Prenatal methadone exposure disrupts behavioral development and alters motor neuron intrinsic properties and local circuitry
Despite the rising prevalence of methadone treatment in pregnant women with opioid use disorder, the effects of methadone on neurobehavioral development remain unclear. We developed a translational mouse model of prenatal methadone exposure (PME) that resembles the typical pattern of opioid use by pregnant women who first use oxycodone then switch to methadone maintenance pharmacotherapy, and subsequently become pregnant while maintained on methadone. We investigated the effects of PME on physical development, sensorimotor behavior, and motor neuron properties using a multidisciplinary approach of physical, biochemical, and behavioral assessments along with brain slice electrophysiology and in vivo magnetic resonance imaging. Methadone accumulated in the placenta and fetal brain, but methadone levels in offspring dropped rapidly at birth which was associated with symptoms and behaviors consistent with neonatal opioid withdrawal. PME produced substantial impairments in offspring physical growth, activity in an open field, and sensorimotor milestone acquisition. Furthermore, these behavioral alterations were associated with reduced neuronal density in the motor cortex and a disruption in motor neuron intrinsic properties and local circuit connectivity. The present study adds to the limited body of work examining PME by providing a comprehensive, translationally relevant characterization of how PME disrupts offspring physical and neurobehavioral development.
- 16 March 2021
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 10
Open AccessPrenatal methadone exposure disrupts behavioral development and alters motor neuron intrinsic properties and local circuitry
Despite the rising prevalence of methadone treatment in pregnant women with opioid use disorder, the effects of methadone on neurobehavioral development remain unclear. We developed a translational mouse model of prenatal methadone exposure (PME) that resembles the typical pattern of opioid use by pregnant women who first use oxycodone then switch to methadone maintenance pharmacotherapy, and subsequently become pregnant while maintained on methadone. We investigated the effects of PME on physical development, sensorimotor behavior, and motor neuron properties using a multidisciplinary approach of physical, biochemical, and behavioral assessments along with brain slice electrophysiology and in vivo magnetic resonance imaging. Methadone accumulated in the placenta and fetal brain, but methadone levels in offspring dropped rapidly at birth which was associated with symptoms and behaviors consistent with neonatal opioid withdrawal. PME produced substantial impairments in offspring physical growth, activity in an open field, and sensorimotor milestone acquisition. Furthermore, these behavioral alterations were associated with reduced neuronal density in the motor cortex and a disruption in motor neuron intrinsic properties and local circuit connectivity. The present study adds to the limited body of work examining PME by providing a comprehensive, translationally relevant characterization of how PME disrupts offspring physical and neurobehavioral development.